Evidence map›Paper›PMID 34306744›Full record

ArticleJournal of ophthalmology2021

Efficacy and Safety of Combined Surgeries including Intraocular Direct Cyclophotocoagulation with a 532 nm Laser to Treat Advanced Neovascular Glaucoma.

Xiaomin Chen, Tian Zheng, Wen Zeng, Xia Fu, Shun Wang, Weijuan Zeng, Min Ke

Open access · goldAbstract read
In one paragraph

Article in Journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaomin ChenDepartment of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Tian ZhengDepartment of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Wen ZengDepartment of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Xia FuDepartment of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Shun WangDepartment of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Weijuan ZengDepartment of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.
Min KeDepartment of Ophthalmology, Zhongnan Hospital, Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0003-2174-4669
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to assess the efficacy and safety of intraocular direct cyclophotocoagulation (IDCP) using a 532 nm laser with combination treatment in reducing intraocular pressure (IOP) for patients with advanced neovascular glaucoma (NVG) with angle closure. In addition, we sought to determine the success rate and frequency of complications and explore an optimized solution to reduce the number of topical medications and the pain of patients.

methodsA retrospective case note review of all patients undergoing combined treatment including IVR, phaco, PPV, PRP, and IDCP from January 2017 to June 2018.

resultsIn total, 24 consecutive patients (25 eyes) were reviewed. The mean IOP was significantly decreased from 42.2 ± 8.5 mmHg preoperatively to 15.56 ± 2.0 mmHg (

conclusionsDuring 18 months of follow-up, the combined treatments were safe and had a significant IOP-lowering effect. This study provides a new method of performing IDCP with a 532 nm laser, allowing for the use of internal cyclophotocoagulation without extra equipment.

Identifiers

PMID34306744
PMCPMC8282404
OpenAlexW3182150823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.